1
|
Aqel SI, Kraus EE, Jena N, Kumari V, Granitto MC, Mao L, Farinas MF, Zhao EY, Perottino G, Pei W, Lovett-Racke AE, Racke MK, Fuchs JR, Li C, Yang Y. Novel small molecule IL-6 inhibitor suppresses autoreactive Th17 development and promotes T reg development. Clin Exp Immunol 2019; 196:215-225. [PMID: 30615197 DOI: 10.1111/cei.13258] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/03/2019] [Indexed: 12/16/2022] Open
Abstract
Multiple sclerosis (MS) is the leading cause of non-traumatic neurological disability in the United States in young adults, but current treatments are only partially effective, making it necessary to develop new, innovative therapeutic strategies. Myelin-specific interleukin (IL)-17-producing T helper type 17 (Th17) cells are a major subset of CD4 T effector cells (Teff ) that play a critical role in mediating the development and progression of MS and its mouse model, experimental autoimmune encephalomyelitis (EAE), while regulatory T cells (Treg ) CD4 T cells are beneficial for suppressing disease. The IL-6/signal transducer and activator of transcription 3 (STAT-3) signaling pathway is a key regulator of Th17 and Treg cells by promoting Th17 development and suppressing Treg development. Here we show that three novel small molecule IL-6 inhibitors, madindoline-5 (MDL-5), MDL-16 and MDL-101, significantly suppress IL-17 production in myelin-specific CD4 T cells in a dose-dependent manner in vitro. MDL-101 showed superior potency in suppressing IL-17 production compared to MDL-5 and MDL-16. Treatment of myelin-specific CD4 T cells with MDL-101 in vitro reduced their encephalitogenic potential following their subsequent adoptive transfer. Furthermore, MDL-101 significantly suppressed proliferation and IL-17 production of anti-CD3-activated effector/memory CD45RO+ CD4+ human CD4 T cells and promoted human Treg development. Together, these data demonstrate that these novel small molecule IL-6 inhibitors have the potential to shift the Teff : Treg balance, which may provide a novel therapeutic strategy for ameliorating disease progression in MS.
Collapse
Affiliation(s)
- S I Aqel
- Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - E E Kraus
- Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - N Jena
- Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.,Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA
| | - V Kumari
- Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA
| | - M C Granitto
- Neuroscience Program, College of Arts and Sciences, The Ohio State University, Columbus, OH, USA
| | - L Mao
- Department of Medicinal Chemistry, University of Florida, Gainsville, FL, USA
| | - M F Farinas
- Neuroscience Program, College of Arts and Sciences, The Ohio State University, Columbus, OH, USA
| | - E Y Zhao
- Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - G Perottino
- Neuroscience Program, College of Arts and Sciences, The Ohio State University, Columbus, OH, USA
| | - W Pei
- Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - A E Lovett-Racke
- Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - M K Racke
- Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - J R Fuchs
- Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA
| | - C Li
- Department of Medicinal Chemistry, University of Florida, Gainsville, FL, USA
| | - Y Yang
- Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.,Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| |
Collapse
|